

HB0346/182816/1

BY: House Judiciary Committee

AMENDMENTS TO HOUSE BILL 346

(First Reading File Bill)

AMENDMENT NO. 1

On page 1, in line 7, after “distributed;” insert “providing that synthetic cannabinoids do not include certain drugs approved by or under development for certain purposes by the federal Food and Drug Administration:”.

AMENDMENT NO. 2

On page 3, in line 24, strike “IS” and substitute “ACTS AS”; strike beginning with “AND” in line 24 down through “CANNABINOID” in line 25; and in line 27, after “INCLUDES” insert “:

(I)”.

On page 4, in line 3, after “II” insert “;AND

(II) A SUBSTANCE OR AN ANALOG OF A SUBSTANCE WITH A STRUCTURAL CLASS BASED ON THE FOLLOWING SPECIFIC CENTRAL OR CORE PHARMACOPHORE:

1. SUBSTITUTED CORE CYCLOHEXYLPHENOLS EXEMPLIFIED BY CP-47497 [5-(1,1-DIMETHYLHEPTYL)-2-[(1R,3S)-3-HYDROXYCYCLOHEXYL]-PHENOL];

2. SUBSTITUTED CORE INDOLES EXEMPLIFIED BY JWH 018 [(1-PENTYL-1H-INDOL-3-YL)-1-NAPHTHALENYL-METHANONE], PB-22 [QUINOLIN-8-YL 1-PENTYL-1H-INDOLE-3-CARBOXYLATE], AND XLR-11 [H-INDOL-3-YL)(2,2,3,3-TETRAMETHYLCYCLOPROPYL)METHANONE];

(Over)

3. SUBSTITUTED CORE INDAZOLES EXEMPLIFIED BY AKB-48 [1-ENTYL-N-TRICYCLO[3.3.1.1³,7]DEC-1-YL-1H-INDAZOLE-3-CARBOXAMIDE] AND AB-CHMINACA [N-(1-AMINO-3-METHYL-1-OXOBUTAN-2-YL)-1-(CYCLOHEXYLMETHYL)-1H-INDAZOLE-3-CARBOXAMIDE];

4. SUBSTITUTED CORE BENZIMIDAZOLES AND AZAINDOLES EXEMPLIFIED BY BIM-2201 [(1-(5-FLUOROPENTYL)-1H-BENZO[D]IMIDAZOL-2-YL(NAPHTHALEN-1-YL)METHANONE] AND 5-FLUOROPCN [1-(5-FLUOROPENTYL)-N-(NAPHTHALEN-1-YL)-1H-PYRROLO[3,2-C]PYRIDINE-3-CARBOXAMIDE];

5. SUBSTITUTED CORE PYRROLES AND PYRAZOLES EXEMPLIFIED BY JWH-307 [[5-(2-FLUOROPHENYL)-1-PENTYL-1H-PYRROL-3-YL]-1-NAPHTHALENYL-METHANONE] AND AZ-037 [N-(1-AMINO-3-METHYL-1-OXOBUTAN-2-YL)-1-(5-FLUOROPENTYL)-3-(4-FLUOROPHENYL)-1H-PYRAZOLE-5-CARBOXAMIDE]; OR

6. SUBSTITUTED CORE CARBAZOLES EXEMPLIFIED BY EG2201 [(9-(5-FLUOROPENTYL)-9H-CARBAZOL-3-YL)(NAPHTALEN-1-YL)METHANONE”;

in line 4, after “THAT” insert “;

(I)”;

and in line 5, after “ADMINISTRATION” insert “; OR

(II) IS UNDER DEVELOPMENT FOR MEDICAL PURPOSES
UNDER AN INVESTIGATIONAL NEW DRUG APPLICATION APPROVED BY THE
FEDERAL FOOD AND DRUG ADMINISTRATION".